NCT03223610 2026-04-20
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
National Institutes of Health Clinical Center (CC)
Phase 1/2 Recruiting
Clinical Trials
12 trialsNCT03960840 2026-04-17
Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL
Novartis
Phase 1/2 Active not recruiting
NCT06536049 2026-02-19
Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
Ohio State University Comprehensive Cancer Center
Phase 1/2 Recruiting
NCT04607772 2025-10-03
Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)
Karyopharm Therapeutics Inc
Phase 1/2 Withdrawn
NCT04446962 2025-09-25
LOC-R01
Institut Curie
Phase 1/2 Active not recruiting
NCT03129828 2024-12-13
ImbruVeRCHOP
Charite University, Berlin, Germany
Phase 1/2 Completed
NCT03310619 2024-04-04
PLATFORM
Celgene
Phase 1/2 Completed
NCT03684694 2024-02-06
Safety and Efficacy Study of Loncastuximab Tesirine + Ibrutinib in Diffuse Large B-Cell or Mantle Cell Lymphoma
ADC Therapeutics S.A.
Phase 1/2 Terminated
NCT02733042 2023-11-18
FUSION NHL 001
Celgene
Phase 1/2 Completed
NCT02760485 2023-06-15
A Study of Itacitinib (INCB039110) in Combination With Ibrutinib in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Incyte Corporation
Phase 1/2 Completed
NCT02077166 2022-02-04
Ibrutinib in Combination With Lenalidomide and Rituximab in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Pharmacyclics LLC.
Phase 1/2 Completed
NCT02401048 2019-06-27
A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Lymphomas
Pharmacyclics LLC.
Phase 1/2 Completed